$127.31
+5.93 (+4.89%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where KYMR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 1 observational
Held by 10 tracked-famous managers (Holocene Advisors, LP, TWO SIGMA INVESTMENTS, LP, MARSHALL WACE, LLP, CITADEL ADVISORS LLC, Squarepoint Ops LLC, +5 more) · FINRA short interest 18.1 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 137 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma StudyNCT07677059Incidence of treatment-emergent adverse events (TEAEs)Open-label · Treatment | Phase 2 | Recruiting | Drug: KT-621 | Asthma (Diagnosis) | 264 | Dec 2028 | ≤ 864 d | 2026-06-30 |
| A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic AsthmaNCT07323654Change from baseline in pre-bronchodilator FEV1Randomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: KT-621 · Other: Placebo | Eosinophilic Asthma | 264 | Dec 2027 | ≤ 498 d | 2026-08-17 |
| A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic DermatitisNCT07217015Change from baseline in Eczema Area and Severity Index (EASI) scoreRandomized · Triple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: KT-621 · Other: Placebo | Atopic Dermatitis | 200 | Jun 2027 | ≤ 314 d | 2026-06-30 |
| First-in-human Study of Orally Administered KT-579 in Healthy Adult ParticipantsNCT07412288Incidence of adverse eventsRandomized · Double-masked · Other | Phase 1 | Recruiting | Drug: KT-579, Placebo | Healthy Participants | 96 | Dec 2026 | ≤ 133 d | 2026-02-27 |
| Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)NCT06945458Incidence of adverse events (AEs)Open-label · Treatment | Phase 1 | Completed | Drug: KT-621 | Atopic Dermatitis | 22 | 2025-11-10actual | — | 2026-01-26 |
| First-in-human Study of Orally Administered KT-621 in Healthy Adult ParticipantsNCT06673667Incidence of adverse eventsRandomized · Double-masked · Other | Phase 1 | Completed | Drug: KT-621, Placebo | Healthy Participants Study | 118 | 2025-04-23actual | — | 2025-10-02 |
| Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid TumorsNCT05225584SafetyNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: KT-333 | Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), T-cell Prolymphocytic Leukemia (T-PLL), Solid Tumors | 56 | 2025-03-03actual | — | 2025-03-19 |
| Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid TumorsNCT05775406Incidence and severity of adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: KT-253 | Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors | 52 | 2024-12-18actual | — | 2025-01-27 |
| Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHLNCT05233033To establish the Maximum Tolerated Dose (MTD)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: KT-413 | Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL, MYD88 Gene Mutation | 7 | 2023-07-28actual | — | 2024-12-10 |
| A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)NCT04772885Incidence and severity of treatment emergent Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: KT-474/Placebo, KT-474 | Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa | 154 | 2022-10-20actual | — | 2022-10-24 |
| Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic DermatitisNCT04440410observationalBiomarker Identification | — | Completed | — | Hidradenitis Suppurativa, Dermatitis, Atopic | 40 | 2021-03-24actual | — | 2021-04-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19